Fig. 3
Downstream enhancers prevent development of inflammatory pathology and autoimmunity. a Growth curves of BAC transgenic and control mice. n ≥ 10 per Tg group. b Growth curves of C57BL/6 mice chimeric for bone marrow from BAC transgenic or Tnfaip3−/− mice. n = 9 per group. Error bars indicate mean ± s.e.m., statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparison test, *P < 0.05; **P < 0.01; ***P < 0.001. c, d Survival data for LPS-challenged mice shown in tabulated form (c) or as Kaplan–Meier plot (d). Data pooled from two experiments, n = 16 for transgenic mice. e Photographs of hind paws of CTR and Δ-DOWN mice at the age ≥ 6 months (top). Photomicrographs of H&E-stained sections of paws and digits; scale bars, 2 mm (bottom). f The cumulative incidence of arthritis in CTR (n = 5 for females and 7 for males) and Δ-DOWN (n = 8 for females and 5 for males) mice starting at 6 months and monitored up to 12 months of age. g mRNA levels of Cxcl9, Cxcl10, and Il1b in cells isolated from hind paws of CTR (n = 3) and Δ-DOWN (n = 3) mice at the age ≥ 6 months. Results are shown as mean ± s.e.m. *P < 0.05, paired t-test
